

# Michael P Mcdermott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1169891/publications.pdf>

Version: 2024-02-01

60  
papers

2,042  
citations

257450

24  
h-index

265206

42  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2637  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Idiopathic Intracranial Hypertension Treatment Trial. <i>JAMA Neurology</i> , 2014, 71, 693.	9.0	336
2	Cognition and mood in perimenopause: A systematic review and meta-analysis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 142, 90-98.	2.5	210
3	Combining dependent P-values. <i>Statistics and Probability Letters</i> , 2002, 60, 183-190.	0.7	121
4	A controlled trial of remacemide hydrochloride in Huntington's disease. <i>Movement Disorders</i> , 1996, 11, 273-277.	3.9	100
5	Quality of life in idiopathic intracranial hypertension at diagnosis. <i>Neurology</i> , 2015, 84, 2449-2456.	1.1	79
6	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. <i>Pain</i> , 2020, 161, 2446-2461.	4.2	64
7	Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. <i>Contemporary Clinical Trials</i> , 2017, 58, 34-39.	1.8	56
8	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	2.8	56
9	Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA). <i>Neurology</i> , 2018, 91, e1206-e1214.	1.1	55
10	High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2. <i>Neurology</i> , 2017, 89, 1348-1354.	1.1	52
11	Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2). <i>Neurology</i> , 2015, 85, 2136-2146.	1.1	44
12	Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). , 2016, 57, 805.		44
13	Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD). <i>Neurology</i> , 2019, 93, e1180-e1192.	1.1	43
14	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1456.	7.4	43
15	Deep Phenotyping of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 855-873.	2.8	42
16	CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. <i>Journal of Neurology</i> , 2015, 262, 2271-2274.	3.6	40
17	Relationships between <i>DMD</i> mutations and neurodevelopment in dystrophinopathy. <i>Neurology</i> , 2019, 93, e1597-e1604.	1.1	40
18	Chemotherapy-induced peripheral neuropathy clinical trials. <i>Neurology</i> , 2017, 89, 859-869.	1.1	37

#	ARTICLE	IF	CITATIONS
19	Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations. <i>Journal of Pain</i> , 2020, 21, 931-942.	1.4	37
20	Quality of life at 6 months in the Idiopathic Intracranial Hypertension Treatment Trial. <i>Neurology</i> , 2016, 87, 1871-1877.	1.1	36
21	Composite outcomes for pain clinical trials: considerations for design and interpretation. <i>Pain</i> , 2021, 162, 1899-1905.	4.2	35
22	Nusinersen Treatment in Adults With Spinal Muscular Atrophy. <i>Neurology: Clinical Practice</i> , 2021, 11, e317-e327.	1.6	35
23	Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. <i>BMC Neurology</i> , 2019, 19, 224.	1.8	28
24	Meta-analysis with missing study-level sample variance data. <i>Statistics in Medicine</i> , 2016, 35, 3021-3032.	1.6	27
25	Interpretation of CIs in clinical trials with non-significant results: systematic review and recommendations. <i>BMJ Open</i> , 2017, 7, e017288.	1.9	26
26	A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial. <i>Trials</i> , 2018, 19, 291.	1.6	26
27	Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. <i>Annals of Neurology</i> , 2000, 48, 590-602.	5.3	24
28	Photographic Reading Center of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT): Methods and Baseline Results. , 2015, 56, 3292.		24
29	Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 204-210.	4.7	24
30	Assay Sensitivity of Pain Intensity Versus Pain Relief in Acute Pain Clinical Trials: ACTION Systematic Review and Meta-Analysis. <i>Journal of Pain</i> , 2015, 16, 683-691.	1.4	23
31	Facioscapulohumeral muscular dystrophy functional composite outcome measure. <i>Muscle and Nerve</i> , 2018, 58, 72-78.	2.2	21
32	The Role of Multifamily Therapy in Promoting Retention in Treatment of Alcohol and Cocaine Dependence. <i>American Journal on Addictions</i> , 1998, 7, 61-73.	1.4	18
33	John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials. <i>Pain</i> , 2020, 161, S3-S13.	4.2	18
34	Reporting of cross-over clinical trials of analgesic treatments for chronic pain: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review and recommendations. <i>Pain</i> , 2016, 157, 2544-2551.	4.2	16
35	Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?. <i>Neurology</i> , 2015, 84, 1620-1621.	1.1	15
36	Navigating trials of personalized pain treatments: we're going to need a bigger boat. <i>Pain</i> , 2019, 160, 1235-1239.	4.2	15

#	ARTICLE	IF	CITATIONS
37	Generalized orthogonal contrast tests for homogeneity of ordered means. Canadian Journal of Statistics, 1999, 27, 457-470.	0.9	14
38	Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients. Neuromuscular Disorders, 2015, 25, 625-631.	0.6	12
39	In-vivo reflectance confocal microscopy of Meissner's corpuscles in diabetic distal symmetric polyneuropathy. Journal of the Neurological Sciences, 2017, 378, 213-219.	0.6	12
40	A Comparison of the Assay Sensitivity of Average and Worst Pain Intensity in Pharmacologic Trials: An ACTTION Systematic Review and Meta-Analysis. Journal of Pain, 2018, 19, 953-960.	1.4	12
41	Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2021, 8, 1086-1095.	3.7	11
42	Neurocognitive Changes after Sustained Ketamine Administration in Children with Chronic Pain. Journal of Palliative Care & Medicine, 2015, 05, .	0.1	10
43	Myotonic dystrophy patient preferences in patient-reported outcome measures. Muscle and Nerve, 2018, 58, 49-55.	2.2	10
44	Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review. Journal of Clinical Epidemiology, 2017, 83, 101-107.	5.0	9
45	Anxiety Symptoms Differ in Youth With and Without Tic Disorders. Child Psychiatry and Human Development, 2021, 52, 301-310.	1.9	9
46	A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design. Journal of Parkinson's Disease, 2020, 10, 1195-1207.	2.8	8
47	Efficacy of Visual Retraining in the Hemianopic Field after Stroke. Ophthalmology, 2021, 128, 1091-1101.	5.2	4
48	Health related quality of life in young, steroid-naïve boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 1161-1168.	0.6	4
49	Risk Behaviors in Youth With and Without Tourette Syndrome. Pediatric Neurology, 2022, 126, 20-25.	2.1	4
50	Generalized multiple contrast tests in dose-response studies. Statistics in Medicine, 2020, 39, 757-772.	1.6	3
51	Testing Equality of Means Under Order Restrictions Using Multiple Contrasts. Communications in Statistics - Theory and Methods, 2008, 37, 3029-3039.	1.0	2
52	Ethical considerations in the design, execution, and analysis of clinical trials of chronic pain treatments. Pain Reports, 2019, 4, e646.	2.7	2
53	Psychometric properties of the PEDI-CAT for children and youth with spinal muscular atrophy. Journal of Pediatric Rehabilitation Medicine, 2021, 14, 451-461.	0.5	2
54	Ankle bracing practices in ambulatory, corticosteroid-naïve boys with Duchenne muscular dystrophy. Muscle and Nerve, 2020, 61, 52-57.	2.2	1

#	ARTICLE	IF	CITATIONS
55	Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. <i>Annals of Neurology</i> , 2000, 48, 590-602.	5.3	1
56	Adaptive dose-response studies to establish proof-of-concept in learning-phase clinical trials. <i>Biometrical Journal</i> , 2022, 64, 146-164.	1.0	1
57	Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. <i>Journal of Huntington's Disease</i> , 2017, 6, 149-156.	1.9	0
58	Huntington's Disease and Hypertension: Sorting Out Mixed Messages. <i>Movement Disorders</i> , 2020, 35, 915-917.	3.9	0
59	When should non-significant results influence clinical decisions?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 548-549.	2.3	0
60	Regarding the Idiopathic Intracranial Hypertension Treatment Trial. <i>Rhode Island Medical Journal</i> (2013), 2016, 99, 9.	0.2	0